NDAINJECTIONINJECTABLE
Approved
Jul 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ULTIVA (remifentanil hydrochloride) is a potent synthetic opioid agonist administered by injection for anesthesia and analgesia in perioperative settings. It is a rapid-onset, short-acting mu-opioid receptor agonist metabolized by non-specific plasma and tissue esterases, enabling quick offset independent of organ function. The drug is used as an analgesic component of balanced anesthesia during induction and maintenance of general anesthesia and for analgesia during monitored anesthesia care.
LOE Approaching
As LOE approaches, commercial teams will focus on maximizing final years of exclusivity through hospital contract renewals and defending against generic erosion in the operating room market.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults
Started Sep 2026
4,670 enrolled
Pneumococcal Disease
Safety and Immunogenicity Study of a Multivalent Gonorrhoea Vaccine
Started Aug 2026
142 enrolled
Neisseria Gonorrhea
A Mindfulness-Based Intervention to Reduce Stress Through the Cultivation of Loving-Kindness, Compassion, Joy, and Equanimity in Healthcare Professionals
Started Oct 2025
80 enrolled
Stress (Psychology)InflamationPsychosocial Functioning
Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants
Started Nov 2022
1,800 enrolled
Streptococcus Pneumoniae Infection
Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women
Started Aug 2022
306 enrolled
Group B Streptococcus Infections
Worked on ULTIVA at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.